Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IAPP | P10997 | 4/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | BID | P55957 | 3/20 | 0.31 |
| ▸ | BCL2L1 | Q07817 | 3/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.31 |
| ▸ | BAK1 | Q16611 | 3/20 | 0.31 |
| ▸ | MMP2 | P08253 | 2/20 | 0.31 |
| ▸ | F7 | P08709 | 2/20 | 0.31 |
| ▸ | F3 | P13726 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2455077 | 1.00 | IAPP (0.40) | IAPPTLR8OPRD1CA1CA2 | |
| SCHEMBL30735542 | 0.81 | IAPP (0.58) | IAPPTLR8CA1CA2MAPT | |
| SCHEMBL30337793 | 0.80 | CA2 (0.50) | IAPPTLR8CA1CA2NFKB1 | |
| SCHEMBL3415698 | 0.80 | CA2 (0.50) | IAPPTLR8CA1CA2NFKB1 | |
| SCHEMBL3415700 | 0.80 | CA2 (0.50) | IAPPTLR8CA1CA2NFKB1 | |
| SCHEMBL13845332 | 0.79 | IAPP (0.38) | IAPPCA1CA2NFKB1CA4 | |
| SCHEMBL5431024 | 0.78 | IAPP (0.46) | IAPPTLR8MAPTGABRA1ERN1 | |
| SCHEMBL4803499 | 0.77 | F7 (0.41) | IAPPOPRD1MAPTBIDBCL2L1 | |
| SCHEMBL26046303 | 0.75 | NFKB1 (0.62) | IAPPCA1CA2NFKB1CA4 | |
| SCHEMBL10584572 | 0.74 | TTR (0.42) | IAPPTLR8CA1CA2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240269192-A1 | FIBROBLAST BASED THERAPEUTICS OF AMYOTROPHIC LATERAL SCLEROSIS | SPINALCYTE LLC (US) | 2024-08-15 | — | — | US | claimed |
| EP-4355342-A1 | FIBROBLAST BASED THERAPEUTICS OF AMYOTROPHIC LATERAL SCLEROSIS | Spinalcyte, LLC (US) | 2024-04-24 | — | — | EP | claimed |
| US-20240024363-A1 | TREATMENT OF LIMB ISCHEMIA BY BONE MARROW STEM CELLS AND MODIFICATION OF DISEASED MICROENVIRONMENT | CREATIVE MEDICAL TECHNOLOGIES, INC. (US) | 2024-01-25 | — | — | US | claimed |
| US-20230364143-A1 | PROTECTION FROM OVARIAN FAILURE BY LOW DOSE INTERLEUKIN-2 ADMINISTRATION | CREATIVE MEDICAL TECHNOLOGIES, INC. (US) | 2023-11-16 | — | — | US | claimed |
| US-20230330193-A1 | ENHANCEMENT OF STEM CELL THERAPY FOR CARTILAGE DEGENERATION BY ANTI-OXIDANT PRE-CONDITIONING | CREATIVE MEDICAL TECHNOLOGIES, INC. (US) | 2023-10-19 | — | — | US | claimed |
| US-20230165918-A1 | REDUCTION OF CYTOKINE STORM AND PATHOLOGICAL INFLAMMATION INCLUDING CAUSED BY CORONAVIRUS USING SPHAGNUM AND EXTRACTS THEREOF | FIGENE, LLC | 2023-06-01 | — | — | US | claimed |
| US-20230141224-A1 | FIBROBLAST MEDIATED EXPANSION AND AUGMENTATION OF IMMUNE REGULATORY CELLS FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) | FIGENE, LLC | 2023-05-11 | — | — | US | claimed |
| EP-4142751-A1 | FIBROBLAST MEDIATED EXPANSION AND AUGMENTATION OF IMMUNE REGULATORY CELLS FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) | Figene, LLC (US) | 2023-03-08 | — | — | EP | claimed |
| WO-2022266485-A1 | FIBROBLAST BASED THERAPEUTICS OF AMYOTROPHIC LATERAL SCLEROSIS | SPINALCYTE LLC (US) | 2022-12-22 | — | — | WO | claimed |
| US-20220395540-A1 | TREATMENT OF COVID-19 LUNG INJURY USING UMBILICAL CORD PLASMA BASED COMPOSITIONS | THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (US) | 2022-12-15 | — | — | US | claimed |
| US-20220362341-A1 | TREATMENT OF MAJOR DEPRESSIVE DISORDER BY LOW DOSE INTERLEUKIN-2 | THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (US) | 2022-11-17 | — | — | US | claimed |
| US-20220175701-A1 | TREATMENT OF MAJOR DEPRESSIVE DISORDER AND SUICIDAL IDEATIONS THROUGH STIMULATION OF HIPPOCAMPAL NEUROGENESIS UTILIZING PLANT-BASED APPROACHES | THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (US) | 2022-06-09 | — | — | US | claimed |
| WO-2021226627-A1 | REDUCTION OF CYTOKINE STORM AND PATHOLOGICAL INFLAMMATION INCLUDING CAUSED BY CORONAVIRUS USING SPHAGNUM AND EXTRACTS THEREOF | FIGENE, LLC (US) | 2021-11-11 | — | — | WO | claimed |
| US-20210330705-A1 | TOLEROGENIC DENDRITIC CELLS FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME | BRAIN CANCER RESEARCH INSTITUTE | 2021-10-28 | — | — | US | claimed |
| WO-2021202032-A1 | FIBROBLAST MEDIATED EXPANSION AND AUGMENTATION OF IMMUNE REGULATORY CELLS FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) | FIGENE, LLC (US) | 2021-10-07 | — | — | WO | claimed |
| US-20210308186-A1 | Treatment of Acute Respiratory Distress Syndrome by T Regulatory Cells | BRAIN CANCER RESEARCH INSTITUTE | 2021-10-07 | — | — | US | claimed |
| US-12559525-B2 | Conjugated fibronectin-binding peptides for use in tumor or fibrosis diagnosis and therapy | ETH Zürich (CH) | 2026-02-24 | — | — | US | disclosed |
| EP-4282490-B1 | FIBRONECTIN-BINDING PEPTIDES FOR USE IN TUMOR OR FIBROSIS DIAGNOSIS AND THERAPY | ETH ZUERICH (CH) | 2025-11-12 | — | — | EP | disclosed |
| US-20030064913-A1 | Treatment and prevention of mucositis in cancer patients | SONIS STEPHEN T (US) | 2003-04-03 | — | — | US | disclosed |
| WO-2003024391-A2 | TREATMENT AND PREVENTION OF MUCOSITIS IN CANCER PATIENTS | MUCOSAL THERAPEUTICS, INC. (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064913-A1 | Treatment and prevention of mucositis in cancer patients | NFKBIA, NFKB2, IKBKG | IAPP 4793/4885TLR8 195/4885OPRD1 747/4885 |
| US-12559525-B2 | Conjugated fibronectin-binding peptides for use in tumor or fibrosis diagnosis and therapy | FN1, ASNS, FNIP1 | IAPP 453/4885TLR8 2993/4885OPRD1 2209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.